ArticleMolecular therapy. Nucleic acids2022

CD16/PD-L1 bi-specific aptamer for cancer immunotherapy through recruiting NK cells and acting as immunocheckpoint blockade.

Aixian Zheng et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.